{"protocolSection": {"identificationModule": {"nctId": "NCT00829179", "orgStudyIdInfo": {"id": "3403"}, "secondaryIdInfos": [{"id": "GCRC 894"}], "organization": {"fullName": "Duke University", "class": "OTHER"}, "briefTitle": "Role of RhuMab-E25 in Reducing Exhaled Nitric Oxide (NO) in Allergic Asthma", "officialTitle": "Role of RhuMab-E25 in Reducing Exhaled NO in Allergic Asthma"}, "statusModule": {"statusVerifiedDate": "2016-01", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2002-10"}, "primaryCompletionDateStruct": {"date": "2004-07", "type": "ACTUAL"}, "completionDateStruct": {"date": "2004-07", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-01-22", "studyFirstSubmitQcDate": "2009-01-23", "studyFirstPostDateStruct": {"date": "2009-01-26", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2009-02-22", "resultsFirstSubmitQcDate": "2009-09-17", "resultsFirstPostDateStruct": {"date": "2009-10-21", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-01-12", "lastUpdatePostDateStruct": {"date": "2016-02-08", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "John Sundy", "investigatorTitle": "Associate Professor", "investigatorAffiliation": "Duke University"}, "leadSponsor": {"name": "Duke University", "class": "OTHER"}, "collaborators": [{"name": "Genentech, Inc.", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "A single center pilot study to determine the protective effects of RhuMAB-E25 on airway physiology and biology in allergic asthmatics that undergo bronchoprovocation with methacholine.\n\nThe primary study objective determines the protective impact of RhuMAB-E25 on airway inflammation as reflected in exhaled nitric oxide (NO) levels in allergic asthmatics.\n\nThe secondary objective determines the protective effect of rhuMAB E25 against airway bronchoconstriction as reflected in the Provocative Concentration of methacholine to cause a 20% fall in FEV1(PC20) with methacholine challenge testing.", "detailedDescription": "This is a single center prospective, open-label study. Eligible subjects will undergo two baseline measurements of exhaled Nitric Oxide (NO) before and after methacholine challenge testing at least one week apart. All subjects will receive treatment with RhuMAB-E25 in an open label fashion at day 0, weeks 4 and 8, and undergo methacholine challenge and NO measurement at screening/baseline, weeks 0, 6, and 12. Complete Blood Count (CBC) will be done at screening/baseline, weeks 1, 2, 4, 8, and week 12. For women of childbearing potential, a screening pregnancy test will be done. All statistical analysis will occur at the conclusion of this study."}, "conditionsModule": {"conditions": ["Allergic Asthma"], "keywords": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "BASIC_SCIENCE", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 20, "type": "ACTUAL"}}, "armsInterventionsModule": {"interventions": [{"type": "DRUG", "name": "RhuMab-E25", "description": "three subcutaneous injections spaced 1 month apart; dose based on subject weight and baseline IgE level.", "otherNames": ["Omalizumab"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in Exhaled Nitric Oxide From Baseline to Week 12", "description": "The primary outcome measure was the change in exhaled nitric oxide levels between baseline and week 12. 12 week value minus baseline value. (Baseline was -1 week, ie 1 week prior to the start of study drug)", "timeFrame": "13 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Subjects must be at least 18 years of age,\n* Must have an FEV1 of \\> 70% of predicted,\n* Must have evidence of bronchial hyperreactivity to methacholine as defined by a methacholine provocation causing a 20% or greater fall in FEV1 (PC20) \\< 8 mg/ml\n* Use of inhaled steroid is permitted; however, no change in inhaled steroid dosage will be permitted over the duration of study\n* Must have a normal platelet count,\n* Must be willing to and competent to sign the consent form\n\nExclusion Criteria:\n\n* Subjects that do not have allergic asthma will be excluded.\n* Subjects with ER visits or upper respiratory infections within the last six weeks will be excluded.\n* Subjects with tobacco use within the past year or \\> 10 pack year history of tobacco use will be excluded.\n* Subjects with serum IgE levels of less than 30 or greater than 700 Iu/mL will be excluded.\n* Subjects that require oral steroid use will be excluded.\n* Subjects who weigh \\< 30 kg or \\> 150 kg are excluded, and subjects with baseline IgE levels greater than 300 may be excluded, depending on weight\n* Pregnant or nursing females will be excluded.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "John S Sundy, MD", "affiliation": "Duke University Medical Director", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Duke University Medical Center", "city": "Durham", "state": "North Carolina", "zip": "27710", "country": "United States", "geoPoint": {"lat": 35.99403, "lon": -78.89862}}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "The majority of screen failures prior to starting study drug was one of 3 reasons; negative methacholine challenge, IgE, too low, or IgE too high.", "recruitmentDetails": "Subjects were recruited from the Pulmonary clinic and the local community from 10/2002 - 07/2004", "groups": [{"id": "FG000", "title": "RhuMab-E25", "description": "Subjects with mild asthma received three doses of study drug subcutaneous injections at one month intervals. Dosing range was 150mg-375mg which was based on baseline IGE and subject body weight.\n\nSubjects with a baseline Ige above 30 and up to 100 with a body weight between 30 and 150kg would receive a study drug dose of 150 mg. Subjects with an IGE 100-200 and body weight 30 - 150 kg would receive a dose of 225 mg. And up to subjects with an IGE of 600-700 only body weight of 30 - 60 would be included with a dose of 375 mg."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "20"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "19"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "RhuMab-E25"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "20"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "20"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "31.8", "spread": "9.1"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "12"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "8"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "20"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change in Exhaled Nitric Oxide From Baseline to Week 12", "description": "The primary outcome measure was the change in exhaled nitric oxide levels between baseline and week 12. 12 week value minus baseline value. (Baseline was -1 week, ie 1 week prior to the start of study drug)", "reportingStatus": "POSTED", "anticipatedPostingDate": "2009-01", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "parts per billion (ppb)", "timeFrame": "13 weeks", "groups": [{"id": "OG000", "title": "RhuMab-E25"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-11.0", "spread": "13.3"}]}]}], "analyses": [{"groupIds": ["OG000"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.005", "statisticalMethod": "Sign test", "paramType": "Difference in Mean", "paramValue": "11.0", "ciPctValue": "95", "dispersionType": "STANDARD_DEVIATION", "dispersionValue": "13.3"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "RhuMab-E25", "seriousNumAffected": 0, "seriousNumAtRisk": 20, "otherNumAffected": 7, "otherNumAtRisk": 20}], "otherEvents": [{"term": "headache", "organSystem": "Nervous system disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 2, "numAtRisk": 20}]}, {"term": "cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 20}]}, {"term": "viral syndrome", "organSystem": "Infections and infestations", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 20}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "Pilot study with small sample size."}, "certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "John S. Sundy M.D. PhD", "organization": "Duke University Medical Center", "email": "john.sundy@duke.edu", "phone": "(919) 668-2169"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000069444", "term": "Omalizumab"}], "ancestors": [{"id": "D000018926", "term": "Anti-Allergic Agents"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}], "browseLeaves": [{"id": "M413", "name": "Omalizumab", "asFound": "Enriched", "relevance": "HIGH"}, {"id": "M12507", "name": "Nitric Oxide", "relevance": "LOW"}, {"id": "M20962", "name": "Anti-Allergic Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AAll", "name": "Anti-Allergic Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}]}}, "hasResults": true}